"I'm excited to be joining such a high-caliber team during an exciting stage of growth," said
Dr. Malloy. "The field of genomics is rapidly evolving from biomarker discovery, to validation and translation into clinical diagnostics, and NanoString's nCounter® platform is uniquely positioned to become the platform-of-choice for complex molecular diagnostics."
"Kirk brings a wealth of knowledge gained at the leading-edge of life science tools and genomics," said President and Chief Executive Officer,
Brad Gray. "He has guided commercial teams through periods of explosive growth, and we look forward to Kirk's perspectives and insights as we focus on our market penetration and scaling the business."
About NanoString Technologies, Inc.